Loading...
Market
Which AI tool developed by Dana-Farber and Weill Cornell will be the first to be widely adopted in clinical settings by mid-2025?
2
Resolution / Starting Odds
UNI • 25%
Virchow • 25%
Prov-GigaPath • 25%
nuclei • 25%
Official adoption announcements and clinical reports
Story
Dana-Farber and Weill Cornell Develop AI Tools to Enhance Digital Pathology
Jul 11, 2024, 07:13 AM
Scientists from Dana-Farber Cancer Institute and Weill Cornell Medicine have developed new artificial intelligence (AI) tools tailored to digital pathology. These tools utilize high-resolution digital images created from tissue samples to help diagnose diseases and guide treatment. The collaboration aims to enhance diagnostic precision and efficiency through AI-pathologist synergy. Researchers, including Gabrielle Campanella and Thomas Fuchs from Icahn School of Medicine at Mount Sinai, have benchmarked eight pathology foundation models, such as UNI, Virchow, and Prov-GigaPath, on large-scale datasets for clinical diagnosis and biomarker discovery. The project also involves MohamedOmarMD, renato_umeton, and TheLancet. Additionally, a digital pathology framework called nuclei has been developed to further boost diagnostic accuracies. This development is part of a growing field that leverages AI to improve healthcare outcomes.
View original story
Similar markets
Machine Learning • 25%
Deep Learning • 25%
Natural Language Processing • 25%
Other • 25%
Fred Hutch • 25%
Dana-Farber Cancer Institute • 25%
Memorial Sloan Kettering Cancer Center • 25%
Johns Hopkins Kimmel Cancer Center • 25%
AWS • 25%
Deloitte • 25%
Microsoft • 25%
Nvidia • 25%
Yes • 50%
No • 50%
MIT • 33%
ETH Zurich • 33%
Other collaborating institution • 33%
None • 1%
Epic Systems • 25%
Cerner • 25%
Allscripts • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%